Theorem Clinical Research

Drug Sponsors

Array BioPharma purchases phase III assets from Novartis

Wednesday, March 4, 2015 01:07 PM

Array BioPharma has completed both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.

More... »

Quest Diagnostics

Teva to sell Sellersville, Pa., facility to G&W Labs

Monday, March 2, 2015 03:08 PM

Jerusalem-based Teva Pharmaceutical Industries will sell its Sellersville, Pa., facility to G&W Laboratories, as part of a plan to streamline operations by reducing excess manufacturing capacity. It is part of Teva’s previously announced cost reduction program.

More... »

GSK, Novartis complete major three-part transaction

Monday, March 2, 2015 03:03 PM

GlaxoSmithKline and Novartis have completed their three-part transaction. As a result, GSK has acquired Novartis' global vaccines business (excluding influenza vaccines) for $5.25 billion and has divested its oncology business to Novartis for $16 billion. In addition, the two have created a new consumer healthcare joint venture in which GSK will have majority control and an equity interest of 63.5%.

More... »

Dicerna Pharmaceuticals moves to Cambridge, Mass., will add 10 jobs

Friday, February 27, 2015 02:30 PM

Dicerna Pharmaceuticals, a developer of RNAi therapeutics, has opened a new 37,000-square-foot office and R&D laboratory in the Alewife area of Cambridge, Mass.

More... »

Biota Pharmaceuticals to acquire Anaconda Pharma

Friday, February 27, 2015 02:29 PM

Biota Pharmaceuticals, based in Alpharetta, Ga., has agreed to acquire Anaconda Pharma, a privately held biotech company based in Paris.

More... »

Sosei acquires Heptares Therapeutics for up to $400M

Wednesday, February 25, 2015 11:36 AM

Sosei Group, a Japanese biopharmaceutical company with operations in Japan and the U.K., has acquired Heptares Therapeutics, a clinical-stage, private U.K.-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors (GPCRs).

More... »

Turing Pharmaceuticals launched

Wednesday, February 25, 2015 11:32 AM

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

More... »

Ipsen to acquire Canbex Therapeutics for $10.2M

Wednesday, February 25, 2015 11:29 AM

Canbex Therapeutics has granted Ipsen, a global specialty-driven pharmaceutical company headquartered in Paris, the exclusive right to purchase 100% of Canbex shares upon completion of the phase IIa study of Canbex’s lead candidate VSN16R for the treatment of spasticity in people with multiple sclerosis (MS).

More... »

Shire acquires Meritage Pharma

Wednesday, February 25, 2015 11:27 AM

Shire has acquired Meritage Pharma, a global, privately held company, for $70 million upfront and additional contingent payments based on development and regulatory milestones.

More... »

Baxter selects northern Illinois site for Baxalta global headquarters

Wednesday, February 25, 2015 11:25 AM

Baxalta, the biopharmaceutical company expected to separate from Baxter International in mid-year, will be headquartered in northern Illinois. A long-term lease agreement for an approximately 260,000-square-foot facility extends for more than a decade.

More... »


March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs